Biotech entity
Grail is most often covered alongside American Society of Clinical Oncology (ASCO), which appears in 1 of these 2 stories. Across a 123-day span, the pace is roughly 0.1 stories per week. Source depth averages 2.5 original sources per story, versus 4.9 across the same-window beat baseline.
Last mentioned: Jul 22, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Grail is most often covered alongside American Society of Clinical Oncology (ASCO), which appears in 1 of these 2 stories. Across a 123-day span, the pace is roughly 0.1 stories per week. Source depth averages 2.5 original sources per story, versus 4.9 across the same-window beat baseline. Their average consequence score of 6 runs below the beat's 6.5 for that window. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. This profile follows 2 Biotech stories mentioning Grail across the period from March 22, 2026 to July 22, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 179 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Grail. Shared-story counts are live from our verified record — not editorial picks.
Gene Solutions' AI-powered multi-cancer liquid biopsy test, SPOT-MAS 10, gains FDA Breakthrough Device Designation after real-world data on 84,145 Asian individuals, signaling a new era for precision oncology emerging from Asia.
Grail (GRAL) shares staged a significant recovery this week, outperforming the broader market following a period of heavy selling. The rebound was driven by a high-profile analyst upgrade and a shift in investor sentiment regarding the company's multi-cancer early detection (MCED) platform.
Grail is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
